📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
56 announcements match the current filters (relevance ≥ 5).
JSLL to Establish 160+ Bed Hospital in Lucknow with ₹3 Crore Investment
Jeena Sikho Lifecare Limited (JSLL) has announced the establishment of a new hospital facility in Lucknow, Uttar Pradesh, spanning approximately 1.25 lakh sq. ft. The facility will feature a capacity of over 160 beds and is scheduled to commence operations by August 2026. The total investment for this project is estimated at ₹3 Crores, which the company plans to fund entirely through internal accruals. This expansion is part of JSLL's strategic objective to scale its Panchakarma healthcare network.
Key Highlights
Establishment of a new 160+ bed hospital facility in Lucknow, Uttar Pradesh.
The facility covers a significant area of approximately 1.25 lakh sq. ft.
Estimated project commencement is set for August 2026.
Total investment of ₹3 Crores to be financed through the company's internal funds.
Expansion aims to increase the reach of specialized Panchakarma services.
👀 What to Watch
Investors should view this as a positive growth step, noting the company's ability to expand using internal funds without taking on debt. Monitor the progress toward the August 2026 launch date to ensure timely execution.
JSLL to Establish New Day Care Clinic in Ayodhya with ₹50 Lakh Investment
Jeena Sikho Lifecare Limited (JSLL) has announced the establishment of a new Day Care Clinic in Ayodhya, Uttar Pradesh, specializing in Panchakarma services. The facility will cover approximately 2,300 sq. ft. and is slated to commence operations by August 2026. The total investment required for this expansion is approximately ₹50 lakhs, which the company plans to fund entirely through internal accruals. This move is part of JSLL's strategic objective to broaden its healthcare network and reach a larger population base.
Key Highlights
New Day Care Clinic to be established in Ayodhya, UP, spanning approximately 2,300 sq. ft.
Total capital expenditure for the project is estimated at ₹50 lakhs.
The expansion will be funded through the company's internal finance (owned funds).
Operations at the new facility are expected to commence by August 2026.
The clinic aims to provide quality Panchakarma services as part of a wider healthcare network expansion.
👀 What to Watch
Investors should view this as a positive step towards organic growth and geographic diversification. The use of internal accruals for expansion suggests a strong cash position and low debt risk.
Jeena Sikho Lifecare Commences Operations of 100-Bed Hospital in Mathura, UP
Jeena Sikho Lifecare Limited (JSLL) has officially commenced operations at its new hospital facility, Sanskriti Ayurvedic P.G. Medical College & Hospital, in Mathura, Uttar Pradesh. The facility is spread across approximately 60,000 sq. ft. and features a 100-bed capacity along with 8 OPD units. This expansion is a key part of the company's strategy to strengthen its Ayurvedic healthcare infrastructure and accessibility in India. The commencement of this facility is expected to contribute to the company's revenue growth and operational presence in the North Indian region.
Key Highlights
Commencement of a new 100-bed hospital facility in Mathura, Uttar Pradesh, effective June 10, 2026.
The facility spans a significant area of approximately 60,000 sq. ft.
Equipped with 8 OPD units to provide integrated and holistic Ayurvedic healthcare services.
Strategic expansion aimed at strengthening the company's healthcare infrastructure and market presence.
👀 What to Watch
Investors should view this as a positive growth milestone and monitor the facility's occupancy rates and contribution to the company's future earnings. The expansion validates the company's commitment to scaling its Ayurvedic healthcare model.
Jeena Sikho Lifecare FY26 PAT Surges 177% to ₹222 Cr; EBITDA Margin Hits 44%
Jeena Sikho Lifecare (JSLL) reported a stellar FY26 with revenue rising 71% to ₹801 crores and PAT jumping 177% to ₹222 crores. The company achieved a significant EBITDA margin of 44%, supported by a 65% increase in IPD patient volumes and strong sales from its Ayurveda product vertical. JSLL remains debt-free and is scaling its infrastructure, targeting up to 10,000 beds in the next 3-5 years. While Q4 saw some one-time accounting provisions, the core business model remains highly capital-efficient with a 71% ROCE.
Key Highlights
FY26 Revenue grew 71% YoY to ₹801 crores; PAT increased 177% to ₹222 crores.
EBITDA margins expanded by 1,360 basis points to reach 44% for the full year.
Ayurveda products contributed 52% of total revenue (₹416 crores) with gross margins exceeding 85%.
Operational beds to increase from 2,300 to 3,000 within 4 months, targeting 10,000 in 5 years.
Zero debt on the balance sheet with a robust 3-year average ROCE of 71%.
👀 What to Watch
The company's high capital efficiency and aggressive expansion into the mainstream healthcare space make it a strong growth play. Investors should monitor the execution of the bed capacity ramp-up and the performance of the new OTC retail segment.
Jeena Sikho Lifecare Q4FY26 PAT Jumps 79% YoY to ₹45.35 Cr; Proposes ₹4.50 Dividend
Jeena Sikho Lifecare Limited (JSLL) reported a robust 55% YoY growth in revenue for Q4 FY26, reaching ₹215.55 crore. Profitability surged significantly with PAT increasing 79% YoY to ₹45.35 crore, driven by strong patient volumes in both IPD and OPD segments. The company has expanded its operational bed capacity to 2,300 and recommended a final dividend of ₹4.50 per share. While YoY performance is strong, EBITDA margins saw a sequential dip to 36% from 45% in Q3 due to one-time provisions for labor codes and ESOPs.
Key Highlights
Revenue from operations grew 55% YoY to ₹215.55 crore in Q4 FY26.
Profit After Tax (PAT) surged 79% YoY to ₹45.35 crore with a PAT margin of 21%.
Board recommended a final dividend of ₹4.50 per equity share of face value ₹2.
Total operational beds reached 2,300 with an additional 561 beds recently added to the network.
IPD patient volumes increased by 70% YoY to 10,911, while OPD volumes grew 56% YoY to 1.50 lakh.
👀 What to Watch
Investors should focus on the company's aggressive capacity expansion and its ability to maintain high margins despite sequential fluctuations. The strong dividend payout and YoY growth trajectory suggest a healthy outlook for the holistic healthcare sector.
JSLL Recommends Rs 4.50 Dividend and Reports FY26 Audited Results with Unmodified Opinion
Jeena Sikho Lifecare Limited (JSLL) has approved its audited financial results for the fiscal year ended March 31, 2026, with the statutory auditors issuing an unmodified opinion. The Board has recommended a final dividend of Rs 4.50 per equity share (225% of face value), pending shareholder approval at the AGM. The audit for FY26 was conducted by Walker Chandiok & Co LLP, marking a transition from the previous auditor KRA & Co. Additionally, the company has re-appointed Forvis Mazars LLP as internal auditors for FY 2026-27.
Key Highlights
Recommended a final dividend of Rs 4.50 per equity share on a face value of Rs 2 for FY 2025-26.
Statutory Auditors Walker Chandiok & Co LLP issued a clean, unmodified audit report for both standalone and consolidated results.
Re-appointed M/s Forvis Mazars LLP as the Internal Auditor for the Financial Year 2026-27.
The audit transition from KRA & Co. to Walker Chandiok & Co LLP was completed successfully for the FY26 reporting cycle.
👀 What to Watch
Investors should view the substantial dividend recommendation and the engagement of a top-tier audit firm as signs of financial health and improved corporate governance. Monitor the upcoming AGM for the final dividend declaration date.
JSLL Recommends ₹4.50 Final Dividend and Approves FY26 Audited Financial Results
Jeena Sikho Lifecare Limited (JSLL) has approved its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026, with an unmodified audit opinion. The Board recommended a final dividend of ₹4.50 per equity share (225% of the ₹2 face value), subject to shareholder approval at the upcoming AGM. Additionally, the company re-appointed Forvis Mazars LLP as the Internal Auditor for FY 2026-27. The statutory audit was conducted by Walker Chandiok & Co LLP, confirming the reliability of the financial disclosures.
Key Highlights
Recommended a final dividend of ₹4.50 per equity share for the financial year 2025-26.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion on the financial results.
Re-appointed M/s Forvis Mazars LLP as Internal Auditor for the 2026-27 financial year.
Transitioned to Indian Accounting Standards (Ind AS) with audited adjustments for the previous year.
👀 What to Watch
Investors should view the substantial dividend recommendation and clean audit report as positive indicators of financial health; monitor the record date for the ₹4.50 dividend payout.
Jeena Sikho Lifecare Recommends Final Dividend of ₹4.50 Per Share for FY26
Jeena Sikho Lifecare Limited (JSLL) has recommended a final dividend of ₹4.50 per equity share for the financial year ended March 31, 2026. This dividend is calculated on a face value of ₹2 per share, representing a 225% payout. The board also approved the audited standalone and consolidated financial results for FY26, which received an unmodified opinion from statutory auditors. Additionally, the company has re-appointed Forvis Mazars LLP as its internal auditor for the 2026-27 fiscal year.
Key Highlights
Recommended a final dividend of ₹4.50 per equity share with a face value of ₹2 for FY 2025-26.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Statutory auditors Walker Chandiok & Co LLP issued an unmodified audit report on the financial statements.
Re-appointed M/s Forvis Mazars LLP as the Internal Auditor for the Financial Year 2026-27.
The dividend payment is subject to shareholder approval at the upcoming Annual General Meeting.
👀 What to Watch
Investors should watch for the announcement of the record date to ensure eligibility for the ₹4.50 dividend and review the detailed financial results to evaluate the company's annual performance.
Jeena Sikho Lifecare to Sell Non-Operational Land in Punjab for ₹24 Crore
Jeena Sikho Lifecare Limited (JSLL) has approved the sale of a non-operational land parcel admeasuring approximately 48 Bigha in Patiala, Punjab. The land is being sold to Tresco Realty Group LLP for a total consideration of ₹24 crore. As the asset is currently idle, the company confirms that the sale will have no impact on its existing business operations. This move is aimed at monetizing non-core assets to potentially strengthen the company's balance sheet.
Key Highlights
Sale of 48 Bigha land parcel located on the Chandigarh–Bathinda Highway in Punjab
Aggregate sale consideration fixed at ₹24,00,00,000 (₹24 Crores)
The transaction is with Tresco Realty Group LLP, a non-related party
No impact on business operations as the land was non-operational
Completion is subject to fulfillment of conditions including the partition (taksim) of the property
👀 What to Watch
Investors should view this as a positive value-unlocking event that improves the company's liquidity without affecting core operations. Monitor the company's future announcements regarding the utilization of these funds for growth or debt reduction.
JSLL to Sell Non-Operational Land in Punjab for ₹24 Crore
Jeena Sikho Lifecare Limited (JSLL) has approved the sale of a non-operational land parcel admeasuring approximately 48 Bigha in Patiala, Punjab. The transaction is valued at ₹24 crore and will be sold to Tresco Realty Group LLP. As the land was not being used for any business activities, the sale will have no impact on the company's current operations. This move is aimed at monetizing idle assets and improving the company's liquidity position.
Key Highlights
Sale of 48 Bigha land located on the Chandigarh–Bathinda Highway in Punjab
Aggregate consideration for the sale is fixed at ₹24,00,00,000 (₹24 Crores)
The buyer, Tresco Realty Group LLP, is not a related party to the company or its promoters
No impact on business operations as the asset was non-operational
Transaction involves an Agreement to Sell executed on May 7, 2026, with board approval on May 8, 2026
👀 What to Watch
Investors should view this as a positive move to unlock value from idle assets. Watch for future disclosures on how the company plans to utilize the ₹24 crore cash inflow, such as for debt reduction or business expansion.
JSLL Noida Hospital Receives NABH Accreditation for Panchakarma Services
Jeena Sikho Lifecare Limited (JSLL) has been awarded the prestigious NABH accreditation for its Noida hospital facility located in Sector 117. This certification specifically covers Panchakarma services and is valid through March 09, 2029. The accreditation signifies the company's adherence to national standards for patient safety and quality healthcare delivery. While this is part of the ordinary course of business, it enhances the company's brand credibility and operational excellence in the Ayurvedic healthcare sector.
Key Highlights
NABH Certificate of Accreditation received for the Noida Hospital facility in Uttar Pradesh.
The accreditation specifically covers Panchakarma services under Certification No. AH-2026-0451.
The certification is valid for a period of approximately 3 years, expiring on March 09, 2029.
Signifies adherence to nationally recognized standards for quality healthcare and patient safety.
👀 What to Watch
Investors should view this as a positive development that strengthens the company's brand and may lead to better insurance tie-ups. No immediate action is required, but it confirms the company's commitment to institutional quality standards.
JSLL Signs Strategic MOU with Sat Kartar Life for Patient Acquisition and Hospital Management
Jeena Sikho Lifecare Limited (JSLL) has entered into a 3-year strategic MOU with Sat Kartar Life Limited (SKL) to integrate data-driven patient acquisition with clinical infrastructure. Under the agreement, JSLL will pay a 15% revenue share on net billing for both OPD and IPD cases referred by SKL, applicable only upon actual payment receipt. The collaboration also explores a model where JSLL provides management services for new Ayurveda hospitals built by SKL, specifically targeting expansion into South India. This performance-linked partnership aims to scale JSLL's patient funnel while maintaining clinical integrity.
Key Highlights
15% revenue share payable to SKL on net billing for both OPD and IPD cases.
Performance-based payment model: JSLL pays only for converted, paying patients, not for leads or appointments.
Strategic expansion into South India via operational management of SKL-owned healthcare facilities.
3-year agreement term focusing on AI-driven patient acquisition and nationwide customer support.
JSLL retains exclusive control over clinical operations, medical protocols, and patient data.
👀 What to Watch
Investors should view this as a low-risk growth strategy due to the performance-linked revenue sharing model. Monitor the execution of the South India expansion and the impact on patient volume in upcoming quarters.
JSLL Dehradun Hospital Receives NABH Accreditation Valid Until January 2029
Jeena Sikho Lifecare Limited (JSLL) has successfully secured the National Accreditation Board for Hospitals & Healthcare Providers (NABH) certification for its Dehradun facility. This accreditation specifically covers Panchakarma services at the Jakhan, Dehradun location and is valid until January 05, 2029. While this does not represent a physical expansion or capacity increase, it validates the company's adherence to high-quality healthcare standards and patient safety. Such certifications are crucial for building brand trust and potentially qualifying for government and insurance empanelments in the future.
Key Highlights
Awarded NABH accreditation for Dehradun Hospital (Jakhan) specifically for Panchakarma services.
The certification (No. AH-2026-0429) is valid for approximately three years until January 05, 2029.
Signifies adherence to nationally recognized standards for quality healthcare delivery and patient safety.
The accreditation occurred in the ordinary course of business and does not involve immediate capacity enhancement.
👀 What to Watch
This is a positive development for long-term brand equity and service quality assurance. Investors should monitor if this accreditation leads to higher patient footfall or new insurance tie-ups for the Dehradun facility.
JSLL to Establish 150-Bed Hospital in Ahmedabad with ₹1.5 Cr Investment
Jeena Sikho Lifecare Limited (JSLL) has announced the establishment of a new 150-bed hospital unit in Sanand, Ahmedabad, Gujarat. The facility will span a significant area of 1,60,000 Sq. Ft. with an estimated investment of ₹1.5 Crore. The project is expected to become operational within the next 6 months, aligning with the company's strategy to strengthen its healthcare footprint in Western India. This expansion is likely to enhance the company's service delivery capacity and revenue potential in the region.
Key Highlights
New hospital unit to be established in Sanand, Ahmedabad with a 150-bed capacity
Total estimated area of the facility is 1,60,000 Sq. Ft.
Projected investment for the establishment is ₹1.5 Crore
Estimated timeline for commencement of operations is within 6 months
👀 What to Watch
Investors should monitor the timely commencement of the facility and its impact on the company's asset turnover and margins. The low capital expenditure relative to the bed capacity suggests an asset-light or efficient scaling model that warrants further observation.
Jeena Sikho Lifecare Q3 FY26 Revenue Surges 92% to ₹221.7 Cr; PAT Jumps 405% YoY
Jeena Sikho Lifecare reported a stellar Q3 FY26 with operational income reaching ₹221.7 crores, driven by a 247% growth in OPD and video consultations. The company achieved a record EBITDA of ₹100.8 crores with margins exceeding 45%, while PAT surged 405% YoY to ₹66.7 crores. Management highlighted a capital-light expansion strategy with a low capex of ₹3-4 lakhs per bed and plans to launch 16 new products by the end of 2026. Bed capacity has reached 2,850, with a focus on increasing occupancy which currently stands at 58%.
Key Highlights
Revenue from operations grew 92% YoY to ₹221.7 crores, with EBITDA crossing the ₹100 crore mark for the first time.
Net profit (PAT) increased by 405% YoY to ₹66.7 crores, maintaining a healthy 30% margin.
Operational bed capacity reached 2,290 with a 58% occupancy rate, while total beds under development stand at 2,850.
Patient volume for OPD and video consultations grew by 247% to 4.34 lakhs during the quarter.
Company plans to launch 16 new products by December 2026 and has initiated international expansion in the UAE.
👀 What to Watch
Investors should note the strong operating leverage and high EBITDA margins as a sign of a robust business model. Monitor the successful rollout of the planned 16 products and the international expansion in the UAE for long-term growth sustainability.
Jeena Sikho Lifecare Approves Q3 FY26 Unaudited Financial Results
Jeena Sikho Lifecare Limited (JSLL) has officially approved its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board meeting was held on February 7, 2026, and concluded with the submission of the limited review report by statutory auditors. This announcement confirms the company's adherence to SEBI Listing Regulations 30 and 33. Investors should now focus on the detailed financial tables to assess the company's performance in the wellness and lifecare sector.
Key Highlights
Board approved unaudited standalone and consolidated results for the quarter ended December 31, 2025.
Statutory Auditors issued a Limited Review Report for the nine-month period ending December 2025.
The board meeting was conducted efficiently, starting at 04:05 P.M. and concluding at 04:35 P.M.
Compliance maintained under Regulation 30 and 33 of SEBI (LODR) Regulations, 2015.
👀 What to Watch
Investors should analyze the detailed financial statements for revenue growth and EBITDA margins once the full report is accessed. Monitor the stock for any price volatility following the earnings release.
JSLL Q3 FY26 Results: Revenue Up 92% YoY, PAT Surges 405% to ₹66.73 Crore
Jeena Sikho Lifecare Limited (JSLL) delivered exceptional Q3 FY26 performance, with revenue growing 92% YoY to ₹221.66 crore. Profitability saw a massive boost as PAT surged 405% YoY to ₹66.73 crore, supported by EBITDA margins expanding from 26% to 45%. The growth was driven by a 247% YoY increase in OPD patient volumes and an 84% rise in IPD volumes. The company is aggressively expanding with 475+ beds in the pipeline, bringing total capacity towards 2,800 beds.
Key Highlights
Revenue from operations increased 92% YoY to ₹221.66 crore in Q3 FY26.
PAT skyrocketed 405% YoY to ₹66.73 crore with PAT margins reaching 30%.
EBITDA margins expanded significantly to 45% compared to 26% in Q3 FY25.
OPD, COD, and Video-Call patient volumes grew 247% YoY to 4.34 lakhs.
Current operational capacity is 2,290 beds with 475+ additional beds under development.
👀 What to Watch
Investors should view the massive margin expansion and volume growth as a sign of high operational leverage and scalability. The company's transition to the mainboard and its aggressive bed expansion pipeline make it a strong growth candidate in the Ayurvedic healthcare sector.
Jeena Sikho Lifecare Approves Q3 FY26 Unaudited Standalone and Consolidated Financial Results
Jeena Sikho Lifecare Limited (JSLL) has announced its financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved both standalone and consolidated unaudited results during their meeting on February 7, 2026. The filing includes the Limited Review Report from statutory auditors, ensuring regulatory compliance under SEBI guidelines. Investors should now focus on the detailed financial statements to evaluate the company's growth and margin performance in the healthcare sector.
Key Highlights
Board approved unaudited standalone and consolidated financial results for the quarter ended Dec 31, 2025.
Statutory auditors provided a Limited Review Report for the nine-month period ending December 2025.
The board meeting was conducted and concluded within a 30-minute window (04:05 P.M. to 04:35 P.M.).
Compliance maintained as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 What to Watch
Investors should scrutinize the detailed profit and loss statements and balance sheet figures to assess the company's operational efficiency. Compare the Q3 results with previous quarters to identify any seasonal trends or growth momentum in the lifecare business.
Jeena Sikho Lifecare Board Approves Unaudited Q3 and Nine-Month FY26 Financial Results
Jeena Sikho Lifecare Limited (JSLL) held a board meeting on February 7, 2026, to approve its financial performance for the period ending December 31, 2025. The board cleared both standalone and consolidated unaudited results, supported by a limited review report from statutory auditors. This meeting marks the official release of Q3 FY26 performance data to the National Stock Exchange and BSE. Investors should now examine the detailed profit and loss statements to evaluate the company's operational efficiency and growth trajectory.
Key Highlights
Board approved unaudited standalone and consolidated financial results for the quarter ended December 31, 2025.
Approval granted for the financial results covering the nine-month period ending December 31, 2025.
Statutory Auditors issued a limited review report on the submitted financial statements.
The board meeting was conducted efficiently, lasting 30 minutes from 4:05 P.M. to 4:35 P.M. IST.
👀 What to Watch
Investors should review the detailed financial tables once published to analyze revenue growth and margin trends. Compare these results against previous quarters to determine if the company is maintaining its growth momentum in the lifecare sector.
Jeena Sikho Lifecare Commences Operations at Two New Hospitals in Siliguri and Bhagalpur
Jeena Sikho Lifecare Limited (JSLL) has officially commenced operations at two new hospital facilities in Siliguri, West Bengal, and Bhagalpur, Bihar, effective February 3, 2026. The Siliguri facility adds 35 beds and 29 rooms, while the Bhagalpur unit adds 25 beds and 18 rooms to the company's healthcare network. Both facilities occupy 10,000 sq. ft. each and include dedicated OPD services. This expansion follows through on proposals initiated in 2025, demonstrating the company's commitment to scaling its physical infrastructure in the Eastern region.
Key Highlights
Commenced operations at two new hospitals in West Bengal and Bihar on February 3, 2026
Siliguri facility features 35 beds, 29 rooms, and 3 OPDs across 10,000 sq. ft.
Bhagalpur facility features 25 beds, 18 rooms, and 2 OPDs across 10,000 sq. ft.
Total capacity addition of 60 beds and 47 rooms across the two new locations
Execution of expansion plans within approximately one year of initial proposal
👀 What to Watch
Investors should view this as a positive operational milestone that will likely contribute to revenue growth in the coming quarters. Monitor the occupancy rates and the company's ability to scale these new centers profitably.
